Oasmia postpones the release of the Q1 report to 26 September and adjusts its financial calendar

NEXT STORY
FDA grants IDE approval to use Oncology Venture’s LiPlaCis DRP for patient selection in a pivotal Phase 3 study
PREV STORY
HealthLynked Reports Record Revenue Growth in 2nd Quarter 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

 Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy ...

author_avatar
NASDAQ Market News

Sensus Healthcare to Host Second Quarter 2019 Financial Results and Business Update Conference Call on August 8, 2019

author_avatar
NASDAQ Market News

Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA)

author_avatar
NASDAQ Market News